<DOC>
	<DOCNO>NCT00344032</DOCNO>
	<brief_summary>Human papillomavirus infection clearly recognize cause cervical cancer . Indeed , infection cervix certain oncogenic type HPV , clear , lead time cervical cancer woman . This study evaluate immune response induce HPV-16/18 L1/AS04 vaccine safety vaccine . The Protocol Posting update order comply FDA Amendment Act , Sep 2007 .</brief_summary>
	<brief_title>Evaluation Immune Safety Response GlaxoSmithKline ( GSK ) Biologicals ' HPV Vaccine Healthy Indian Women</brief_title>
	<detailed_description />
	<mesh_term>Vaccines</mesh_term>
	<criteria>All subject must satisfy follow criterion study entry : Subjects investigator believe comply requirement protocol enrol study . A female , include , 18 35 year age time first vaccination . Written inform consent obtain subject . Healthy subject establish medical history clinical examination enter study . Subjects must negative urine pregnancy test . Subjects childbearing potential time study entry must abstinent must use adequate contraceptive precaution 30 day prior vaccination must agree continue precaution two month completion vaccination series . The following criterion check time study entry . If apply , subject must include study : Use investigational nonregistered product ( drug vaccine ) study vaccine/ control within 30 day precede first dose study vaccine/ control , plan use study period . Pregnant breastfeeding . Planning become pregnant likely become pregnant . Chronic administration immunosuppressant immunemodifying drug within six month prior first vaccine dose . Planned administration/administration vaccine foreseen study protocol within 30 day ( Days 1 30 ) 30 day ( Day 0 Day 29 ) first dose vaccine . Administration routine meningococcal , hepatitis B , inactivate influenza , diphtheria/tetanus and/or diphtheria/tetanuscontaining vaccine 8 day first dose study vaccine allow . Previous administration component investigational vaccine . Previous vaccination HPV . Any medically diagnose suspected immunodeficient condition base medical history physical examination . History allergic disease , suspect allergy reaction likely exacerbate component study vaccine . Hypersensitivity latex . Known acute chronic , clinically significant neurologic , hepatic renal functional pulmonary , cardiovascular abnormality , determine previous physical examination laboratory test . History chronic condition ( ) require treatment . Administration immunoglobulins and/or blood product within three month precede first dose study vaccine/ control plan administration study period . Enrolment deferred condition resolve . Acute disease time enrolment . Acute disease define presence moderate severe illness without fever .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>35 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Double-blind</keyword>
	<keyword>Human Papillomavirus</keyword>
	<keyword>Phase IIIb</keyword>
	<keyword>Controlled</keyword>
	<keyword>Randomized</keyword>
	<keyword>India</keyword>
</DOC>